Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChenavari Toro Regulatory News (TORO)

Share Price Information for Chenavari Toro (TORO)

Share Price is delayed by 15 minutes
Get Live Data
0.5425    -0.0025 (-0.46%)
Bid:
0.53
Ask:
0.555
Spread: 0.025 (4.717%)
Market Cap: €171.68m
TORO Live PriceLast checked at - London Stock Exchange

Intraday Chenavari Toro Share Chart

Tender Offer Results

13 Feb 2020 07:00

RNS Number : 8175C
Chenavari Toro Income Fund Limited
13 February 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION

 

CHENAVARI TORO INCOME FUND LIMITED (the "Company")13 February 2020

 

 

Tender Offer results

Results of Extraordinary General MeetingReissuance parameters

 

 

 

Tender Offer results

 

Further to the Tender Offer launched by the Company on 14 January 2020 for up to 5.0 per cent. of the Shares in issue (excluding any Shares currently held in treasury), the Company today announces that 10,646,641 Shares were validly tendered pursuant to the Tender Offer, representing 3.4 per cent of the Shares in issue. At the Tender Price of EUR 0.8519, this represents a Tender Offer of EUR 9,069,873.15.

 

Qualifying Shareholders who validly tendered a percentage of their Shares equal to or less than their Tender Offer Entitlement shall have all tendered Shares purchased in full at the Tender Price.

 

Results of Extraordinary General Meeting

 

At the Extraordinary General Meeting held at 10.00 a.m. on 12 February 2020 at the offices of Estera Administration (Guernsey) Limited, Floor 2, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 4LY, the Ordinary Resolution as set out in the Notice of Extraordinary General Meeting dated 14 January 2020 authorising the Company to make market purchases pursuant to the Tender Offer and to reissue Treasury Shares was duly passed without amendment.

 

The number of votes for and against the Ordinary Resolution and the number of votes withheld were as follows:

 

 

For

Against

At Discretion

Withheld

152,741,811

3,143,200

893,904

8,000

 

 

"Votes withheld" are not votes in law and are not counted in the calculation of the proportion of votes for or against a resolution.

Shareholders should refer to the Circular for the full terms of the Tender Offer.

 

Reissuance parameters

The Shares purchased by the Company under the Tender Offer will be held as Treasury Shares in accordance with the Law.

 

Immediately following the release of this announcement, investors will have the opportunity, during London Stock Exchange trading hours on 13 February 2020, to participate in the Reissuance, pursuant to which Treasury Shares will be made available to investors for purchase.

 

In order to ensure that the combined effect of the Tender Offer and the Reissuance are not dilutive for remaining Shareholders, the maximum amount of Treasury Shares available for Reissuance will be as follows:

 

- 7,200,000 Treasury Shares to be issued at EUR 0.8018 (floor price equal to 80 per cent. of the 31 December 2019 NAV per Share), or

- 7,300,000 Treasury Shares to be issued at EUR 0.8050, or

- 7,500,000 Treasury Shares to be issued at EUR 0.8100, or

- 7,700,000 Treasury Shares to be issued at EUR 0.8150, or

- 7,900,000 Treasury Shares to be issued at EUR 0.8200, or

- 8,100,000 Treasury Shares to be issued at EUR 0.8250, or

- 8,300,000 Treasury Shares to be issued at EUR 0.8300

 

So far as reasonably practicable, the Company will endeavour to ensure that Treasury Shares will not be sold to Shareholders who participated in the Tender Offer.

Enquiries:

 

Chenavari Investment Managers: Guy Goyard - 020 7245 4672, Kirstie Sumarno - 020 7259 3600J.P. Morgan Cazenove: William Simmonds - 020 7742 4000

 

 

This announcement is not an offer to sell or a solicitation of any offer to buy the securities of Chenavari Toro Income Fund Limited (the "Company") in the United States, Australia, Canada, Japan, The Republic of South Africa or in any other jurisdiction where such offer or sale would be unlawful.

 

This communication is not for publication or distribution, directly or indirectly, in or into the United States of America. This communication is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

 

The information contained in this announcement is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment. In particular, the proposals referred to herein are tentative and are subject to material updating, revision and amendment. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

 

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur. Each of the Company its affiliates and their respective officers, employees and agents expressly disclaim any and all liability which may be based on this announcement and any errors therein or omissions therefrom.

 

This announcement does not constitute or form part of, and should not be construed as, any offer or invitation or inducement for sale, transfer or subscription of, or any solicitation of any offer or invitation to buy or subscribe for or to underwrite, any share in the Company or to engage in investment activity (as defined by the Financial Services and Markets Act 2000) in any jurisdiction nor shall it, or any part of it, or the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision whatsoever, in any jurisdiction.

 

J.P. Morgan Cazenove is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as Corporate Broker to the Company and no one else in connection with the proposals described in this announcement, and will not be responsible to anyone other than the Company for providing the protections afforded to clients of J.P. Morgan Cazenove or for affording advice in relation to any transaction or arrangement referred to in this announcement. This announcement does not constitute any form of financial opinion or recommendation on the part of J.P. Morgan Cazenove or any of its affiliates and is not intended to be an offer, or the solicitation of any offer, to buy or sell any securities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCTTMFTMTBBBLM
Date   Source Headline
29th May 20267:00 amRNSCompany Factsheet Available
27th May 20265:00 pmRNSNet Asset Value(s)
14th May 20265:00 pmRNSScrip Dividend Election
1st May 20267:00 amRNSCompany Factsheet Available
29th Apr 20265:01 pmRNSDividend Declaration
29th Apr 20265:00 pmRNSNet Asset Value(s)
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20265:00 pmRNSCompany Factsheet Available
24th Mar 20265:00 pmRNSNet Asset Value(s)
6th Mar 20265:00 pmRNSShares in Issue
6th Mar 202610:30 amRNSResult of AGM
3rd Mar 20265:00 pmRNSCompany Factsheet Available
25th Feb 20265:00 pmRNSNet Asset Value(s)
13th Feb 20267:00 amRNSScrip Dividend Election
6th Feb 20267:00 amRNSNotice of AGM
29th Jan 20263:58 pmRNSDividend Declaration
29th Jan 20267:01 amRNSCompany Factsheet Available
29th Jan 20267:00 amRNSDividend Declaration
27th Jan 20265:00 pmRNSNet Asset Value(s)
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSCompany Factsheet Available
31st Dec 20257:00 amRNSCompany Factsheet Available
19th Dec 20257:00 amRNSNet Asset Value(s)
18th Dec 20255:00 pmRNSAnnual Report and Audited Financial Statements
18th Dec 20255:00 pmRNSAnnual Report and Audited Financial Statements
5th Dec 20255:00 pmRNSShares in Issue
28th Nov 20257:00 amRNSCompany Factsheet Available
21st Nov 20255:00 pmRNSNet Asset Value(s)
13th Nov 20255:00 pmRNSScrip Dividend Election Price
5th Nov 20255:00 pmRNSShares in Issue
3rd Nov 20255:00 pmRNSQuarterly Investor Webinar
29th Oct 20257:00 amRNSDividend Declaration
22nd Oct 20255:00 pmRNSCompany Factsheet Available
20th Oct 20255:00 pmRNSNet Asset Value(s)
1st Oct 20257:00 amRNSTotal Voting Rights
25th Sep 20255:00 pmRNSCompany Factsheet Available
22nd Sep 20255:00 pmRNSNet Asset Value(s)
19th Sep 20255:00 pmRNSDirector/PDMR Shareholding
5th Sep 20255:00 pmRNSShares in Issue
28th Aug 20257:00 amRNSCompany Factsheet Available
22nd Aug 20255:00 pmRNSNet Asset Value(s)
14th Aug 20255:00 pmRNSScrip Dividend Election Price
25th Jul 20257:01 amRNSQuarterly Investor Webinar
25th Jul 20257:00 amRNSDividend Declaration
23rd Jul 20257:00 amRNSCompany Factsheet Available
18th Jul 20255:00 pmRNSNet Asset Value(s)
1st Jul 20257:00 amRNSTotal Voting Rights
25th Jun 20257:00 amRNSInterim Financial Statements
18th Jun 20255:00 pmRNSCompany Factsheet Available

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.